Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT04328103 Completed - Clinical trials for Major Depressive Disorder

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

Start date: November 25, 2020
Phase:
Study type: Observational [Patient Registry]

This research aims to elucidate mechanisms through which change occurs during cognitive behavior therapy (CBT) for depression. Assessing meta-cognitive processes of self-knowledge (top-down), electrophysiological and behavioral correlates of emotion processing (bottom-up), and their relation to treatment outcome will provide new insights into the mechanisms of emotion regulation deficits in depression. It will also contribute toward the clinical goal of identifying patients who may benefit most from CBT for unipolar depression.

NCT ID: NCT04325100 Completed - Schizophrenia Clinical Trials

Intervention Targeting Motivational Negative Symptoms

Switch
Start date: April 20, 2019
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of the Switch intervention on motivation and associated processes and explore the dynamics between the processes. A single case approach is followed, with a pre-post and follow-up assessment design, and continuous ambulatory assessments (experience sampling method (ESM) and step count).

NCT ID: NCT04322526 Completed - Depression Clinical Trials

Study of Naltrexone-Induced Blockade of Antidepressant Effects

SONRISA2
Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

The goal of this study is to determine whether antidepressant placebo effects and contextual cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone. To test this hypothesis, un-medicated, patients with MDD completed a randomized, double-blind, placebo-controlled, cross-over study of 50mg of the µ-opioid antagonist naltrexone or matching placebo, immediately before a Pharmaco-fMRI scanning session.

NCT ID: NCT04317495 Terminated - Clinical trials for Major Depressive Disorder

Augmenting rTMS With Cognitive Control Training in Major Depressive Disorder

Start date: August 27, 2019
Phase: N/A
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for MDD, but the overall effect sized of the treatment is equivalent to antidepressant pharmacotherapy, and responses are highly variable. Given that rTMS is usually given to patients who have failed pharmacotherapy, a more effective alternative is needed. Therefore, this study will combine computerized cognitive training (CCT) during standard rTMS treatments and assess its feasibility, tolerability, and changes in cognitive control performance and depression symptoms. Participants that agree to the study and meet eligibility will receive standard rTMS (generally 25-36 daily treatments) along with CCT (starting on day 5 of treatment until the pre-taper treatment). In addition, to CCT participants will be asked to complete assessments before and after treatment

NCT ID: NCT04317001 Withdrawn - Clinical trials for Major Depressive Disorder

Treatment for Cognitive Impairment in Depression

T-CID
Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

The proposed study seeks to investigate the effects of modafinil on cognitive function in depression, which holds promise for better treating cognitive impairment in depression, as well as better understand cognitive dysfunction in MDD from a neural rather than diagnostic point of view to better classify and treat these disabling symptoms.

NCT ID: NCT04311619 Suspended - Clinical trials for Major Depressive Disorder

Does rTMS Induce Synaptic Plasticity?

Start date: December 1, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to investigate the effect of repetitive transcranial magnetic stimulation (rTMS) on synaptic plasticity. UCB-J has been validated as a marker for synaptic density. We will use this tracer to examine if rTMS leads to changes in synaptic plasticity, specifically changes in synaptic density, in individuals receiving rTMS for MDD. If rTMS is proven effective for increasing synaptic plasticity, there is a significant potential of a new applicable treatment for a variety of diseases that affect brain physiology.

NCT ID: NCT04296604 Recruiting - Schizophrenia Clinical Trials

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

Start date: September 2014
Phase: N/A
Study type: Interventional

In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.

NCT ID: NCT04295941 Completed - Clinical trials for Major Depressive Disorder

Long-term Study With Trazodone Once-a-Day

Start date: June 23, 2020
Phase:
Study type: Observational

The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, for up to 24 weeks.

NCT ID: NCT04294654 Completed - Clinical trials for Major Depressive Disorder

Vortioxetine in Patients With Depression and Early Dementia

MEMORY
Start date: February 28, 2020
Phase: Phase 4
Study type: Interventional

This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia

NCT ID: NCT04293341 Recruiting - Clinical trials for Major Depressive Disorder

Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/anxiety disorders, including posttraumatic stress disorder. The proposed research seeks to evaluate the efficacy of TBT by assessing psychiatric symptomatology and related impairment outcomes in Veterans with depressive/anxiety disorders via a randomized controlled trial of TBT and existing DSTs in Veterans with major depressive disorder, posttraumatic stress disorder, and panic disorder. Assessments will be completed at pre-, mid-, and post-treatment, and at 6-month follow-up. Process variables also will be investigated.